Product
mRNA-1273.222
4 clinical trials
2 indications
Indication
COVID-19Indication
InfluenzaClinical trial
A Phase 1/2, Randomized, Observer-blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-based Influenza and SARS-CoV-2 Multi-component Vaccines in Healthy AdultsStatus: Active (not recruiting), Estimated PCD: 2024-11-29
Clinical trial
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 VariantsStatus: Completed, Estimated PCD: 2023-11-17
Clinical trial
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2024-06-09
Clinical trial
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19Status: Active (not recruiting), Estimated PCD: 2024-08-23